Search

Your search keyword '"Akagi Y"' showing total 933 results
Start Over Author "Akagi Y"
933 results on '"Akagi Y"'

1. Actual computational time-cost of the Quantum Fourier Transform in a quantum computer using nuclear spins

Author

Saito, A., Kioi, K., Akagi, Y., Hashizume, N., and Ohta, K.

Subjects
Quantum Physics
Abstract

We found that the actual computational time-cost of the QFT is O(n 2^n) for large n in a quantum computer using nuclear spins. The computational cost of a quantum algorithm has usually been estimated as the sum of the universal gates required in such ideal mathematical models as the Quantum Turing Machine(QTM) and the quantum circuit. This cost is proportional to an actual time-cost in the physical implementation where all quantum operations can be achieved in the same time. However, if the implementation takes a different time for each quantum gate, there is a possibility that the actual time-cost will have a different behavior from the ideal cost. So we estimated the actual time-cost of the QFT in these implementations by considering the gating time. The actual time-cost is drastically different from O(n^2) estimated by complexity analysis., Comment: 4pages, LaTeX2e file

Published
2000

2. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study

Author

Takemasa, I., Hakamada, K., Kameyama, H., Takii, Y., Hase, K., Kotake, K., Watanabe, T., Takahashi, K., Kanemitsu, Y., Itabashi, M., Yano, H., Yasuno, M., Hasegawa, H., Hashiguchi, Y., Masaki, T., Watanabe, M., Maeda, K., Komori, K., Sakai, Y., Ohue, M., Akagi, Y., Yamano, Tomoki, Yamauchi, Shinichi, Kimura, Kei, Babaya, Akihito, Hamanaka, Michiko, Kobayashi, Masayoshi, Fukumoto, Miki, Tsukamoto, Kiyoshi, Noda, Masafumi, Tomita, Naohiro, and Sugihara, Kenichi

Published
2017
Full Text
View/download PDF

17. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy. (Scientific Correspondence)

Author

Oishi, N., Kubo, E., Takamura, Y., Maekawa, K., Tanimoto, T., and Akagi, Y.

Subjects
Diabetic retinopathy -- Research -- Complications and side effects, Diabetes -- Complications and side effects -- Research, Ophthalmology -- Research, Health
Abstract

Methods: A clinic based cross sectional study was used. 611 NIDDM patients and 73 controls were enrolled. Erythrocyte AR levels were determined by ELISA. These AR levels were then correlated [...]

Published
2002

20. 421P Upfront chemotherapy vs. surgery for very low lying locally advanced rectal cancer without preoperative chemoradiation: The NAIR phase II/III trial

Author

Tsukada, Y., primary, Nishizawa, Y., additional, Akagi, Y., additional, Koda, K., additional, Ohue, M., additional, Shinto, E., additional, Nishikawa, S., additional, Hanai, T., additional, Sasaki, T., additional, Ikeda, K., additional, Bando, H., additional, Yamanaka, T., additional, Yoshino, T., additional, Saito, N., additional, and Ito, M., additional

Published
2020
Full Text
View/download PDF

21. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212)

Author

Tsukamoto, S, primary, Fujita, S, additional, Ota, M, additional, Mizusawa, J, additional, Shida, D, additional, Kanemitsu, Y, additional, Ito, M, additional, Shiomi, A, additional, Komori, K, additional, Ohue, M, additional, Akazai, Y, additional, Shiozawa, M, additional, Yamaguchi, T, additional, Bando, H, additional, Tsuchida, A, additional, Okamura, S, additional, Akagi, Y, additional, Takiguchi, N, additional, Saida, Y, additional, Akasu, T, additional, and Moriya, Y, additional

Published
2020
Full Text
View/download PDF

23. Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

Author

Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Shono T, Mizoguchi M, and Iihara K

Subjects
glioblastoma, performance status, unresectable, bevacizumab, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, survival, lcsh:RC254-282
Abstract

Nobuhiro Hata,1,2 Koji Yoshimoto,1 Ryusuke Hatae,1 Daisuke Kuga,1 Yojiro Akagi,1 Yuhei Sangatsuda,1 Satoshi O Suzuki,3 Tadahisa Shono,1,4 Masahiro Mizoguchi,1,5 Koji Iihara1 1Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 2Department of Neurosurgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 3Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, 4Department of Neurosurgery, Harasanshin Hospital, Fukuoka, 5Department of Neurosurgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan Purpose: The AVAglio trial established the beneficial effect of add-on bevacizumab (BEV) for the treatment of newly diagnosed glioblastomas (nd-GBMs) that led to the approval of BEV for the treatment of these patients in Japan. However, the rationality of using BEV as a first-line treatment for nd-GBMs remains controversial. The purpose of this study was to analyze the outcomes of a case series of nd-GBM patients.Patients and methods: The outcomes of 69 nd-GBM patients treated after 2006 were retrospectively analyzed. Clinical and genetic analyses were performed, and estimates of progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Since add-on BEV therapy was only used for partially resected GBMs (pr-GBMs) after its approval in 2013, the patients were subdivided into 3 treatment groups: Type I, partial removal with temozolomide (TMZ)/BEV and concurrent radiotherapy (CCRT); Type II, partial removal with TMZ and CCRT; and Type III, gross total removal with TMZ and CCRT.Results: The PFS rate of Type I patients was significantly higher than that of Type II patients (P=0.014), but comparable to that of Type III patients. Differences in OS rates between Type I and Type II patients were less apparent (P=0.075), although the median OS of Type I patients was ~8months higher than that of Type II patients (17.4 vs 9.8months, respectively). The clinical deterioration rate during initial treatment was significantly (P=0.024) lower in TypeI than in Type II patients (7.7% vs 47.4%, respectively). Differences in OS rates between Type I and Type II patients with a poor performance status (PS) were significant (P=0.017).Conclusion: Our findings suggest that add-on BEV can prevent early clinical deterioration of pr-GBM patients and contribute to a prolonged survival, especially for those with a poor PS. Keywords: bevacizumab, glioblastoma, performance status, survival, unresectable

Published
2017

28. Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade

Author

Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Suzuki SO, Iwaki T, Shono T, Mizoguchi M, and Iihara K

Subjects
IDH, PAV, 1p19q codel, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, oligodendroglioma, lcsh:RC254-282
Abstract

Nobuhiro Hata,1,2 Koji Yoshimoto,1 Ryusuke Hatae,1 Daisuke Kuga,1 Yojiro Akagi,1 Satoshi O Suzuki,3 Toru Iwaki,3 Tadahisa Shono,1,4 Masahiro Mizoguchi,1,5 Koji Iihara1 1Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 2Department of Neurosurgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 3Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, 4Department of Neurosurgery, Harasanshin Hospital, Fukuoka, 5Department of Neurosurgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan Abstract: Recently updated phase III trials revealed the favorable effect of add-on procarbazine-lomustine-vincristine chemotherapy (CT) to radiotherapy (RT) in treating anaplastic oligodendrogliomas with 1p19q codeletion (codel). However, the underlying rationality of deferring RT and upfront CT administration for these tumors is yet to be elucidated. Here, we retrospectively analyzed the long-term outcome of our case series with oligodendroglial tumors treated with deferred RT and upfront procarbazine+nimustine+vincristine (PAV) in the introduction administration. We enrolled 36 patients with newly diagnosed oligodendroglial tumors (17, grade II and 19, grade III) treated during 1999–2012 and followed up for a median period of 69.0months. Their clinical and genetic prognostic factors were analyzed, and progression-free survival, overall survival (OS), and deterioration-free survival (DFS) were evaluated. Regardless of the WHO grade, the 25 patients with 1p19q codel tumors never received RT initially, and of these 25, 23 received PAV treatment upfront. The 75% OS of patients with 1p19q codel tumor was 135.3months (did not reach the median OS), indicating a favorable outcome. Multivariate analysis revealed that IDH mutation and 1p19q, not WHO grade, are independent prognostic factors; furthermore, IDH and 1p19q status stratified the cohort into 3 groups with significantly different OS. The DFS explained the prolonged survival without declining performance in patients with both grade II and III 1p19q codel tumors. Deferred RT and upfront PAV treatment for 1p19q codel oligodendrogliomas were associated with favorable outcomes without compromising performance status, regardless of WHO grade. Keywords: oligodendroglioma, IDH, PAV, 1p19q codel

Published
2016

29. Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, phase II study

Author

Makiyama, A., primary, Oki, E., additional, Miyamoto, Y., additional, Kotaka, M., additional, Kawanaka, H., additional, Miwa, K., additional, Kabashima, A., additional, Noguchi, T., additional, Yuge, K., additional, Kashiwada, T., additional, Shimokawa, M., additional, Saeki, H., additional, Akagi, Y., additional, Baba, H., additional, and Mori, M., additional

Published
2019
Full Text
View/download PDF

40. SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results

Author

Takahashi, M., primary, Munemoto, Y., additional, Nakamura, M., additional, Kotaka, M., additional, Kuroda, H., additional, Kato, T., additional, Minagawa, N., additional, Noura, S., additional, Fukunaga, M., additional, Kuramochi, H., additional, Touyama, T., additional, Takahashi, T., additional, Akagi, Y., additional, Satake, H., additional, Kurosawa, S., additional, Miura, T., additional, Mishima, H., additional, Sakamoto, J., additional, Oba, K., additional, and Nagata, N., additional

Published
2018
Full Text
View/download PDF

44. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study

Author

Yamano, Tomoki, primary, Yamauchi, Shinichi, additional, Kimura, Kei, additional, Babaya, Akihito, additional, Hamanaka, Michiko, additional, Kobayashi, Masayoshi, additional, Fukumoto, Miki, additional, Tsukamoto, Kiyoshi, additional, Noda, Masafumi, additional, Tomita, Naohiro, additional, Sugihara, Kenichi, additional, Takemasa, I., additional, Hakamada, K., additional, Kameyama, H., additional, Takii, Y., additional, Hase, K., additional, Kotake, K., additional, Watanabe, T., additional, Takahashi, K., additional, Kanemitsu, Y., additional, Itabashi, M., additional, Yano, H., additional, Yasuno, M., additional, Hasegawa, H., additional, Hashiguchi, Y., additional, Masaki, T., additional, Watanabe, M., additional, Maeda, K., additional, Komori, K., additional, Sakai, Y., additional, Ohue, M., additional, and Akagi, Y., additional

Published
2017
Full Text
View/download PDF

50. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study

Author

Takatsuki, M., primary, Tokunaga, S., additional, Uchida, S., additional, Sakoda, M., additional, Shirabe, K., additional, Beppu, T., additional, Emi, Y., additional, Oki, E., additional, Ueno, S., additional, Eguchi, S., additional, Akagi, Y., additional, Ogata, Y., additional, Baba, H., additional, Natsugoe, S., additional, and Maehara, Y., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results